Ind-Swift Laboratories reports FY23 PAT at Rs. 42.47 Cr
The company reported lifetime high EBIDTA of Rs. 250 crores
The company reported lifetime high EBIDTA of Rs. 250 crores
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Medical Device Policy is a progressive step in propelling the country towards Atmanirbharta in the heavily import dependent Medical Device Sector
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
The product is expected to be launched in June 2023
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
Product deliveries scheduled in Q3 of 2023
Subscribe To Our Newsletter & Stay Updated